[go: up one dir, main page]

BG65150B1 - Кристална полиморфна форма на ритонавир и метод за получаването й - Google Patents

Кристална полиморфна форма на ритонавир и метод за получаването й Download PDF

Info

Publication number
BG65150B1
BG65150B1 BG105197A BG10519701A BG65150B1 BG 65150 B1 BG65150 B1 BG 65150B1 BG 105197 A BG105197 A BG 105197A BG 10519701 A BG10519701 A BG 10519701A BG 65150 B1 BG65150 B1 BG 65150B1
Authority
BG
Bulgaria
Prior art keywords
ritonavir
crystalline
amino
solution
purity
Prior art date
Application number
BG105197A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG105197A (en
Inventor
John Bauer
Azita Saleki-Gerhardt
Bikshandarkoil NARAYANAN
Sanjay Chemburkar
Ketan Patel
Harry Spiwek
Philip Bauer
Kimberly Allen
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG65150(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of BG105197A publication Critical patent/BG105197A/xx
Publication of BG65150B1 publication Critical patent/BG65150B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
BG105197A 1998-07-20 2001-01-30 Кристална полиморфна форма на ритонавир и метод за получаването й BG65150B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04

Publications (2)

Publication Number Publication Date
BG105197A BG105197A (en) 2001-10-31
BG65150B1 true BG65150B1 (bg) 2007-04-30

Family

ID=26817251

Family Applications (4)

Application Number Title Priority Date Filing Date
BG105197A BG65150B1 (bg) 1998-07-20 2001-01-30 Кристална полиморфна форма на ритонавир и метод за получаването й
BG109682A BG65963B1 (bg) 1998-07-20 2006-09-20 Аморфен ритонавир и метод за неговото получаване
BG110080A BG110080A (bg) 1998-07-20 2006-09-20 Ритонавир, метод за неговото получаване и използването му
BG10110080A BG66140B1 (bg) 1998-07-20 2008-03-12 Фармацевтичен състав, съдържащ кристална форма іі ритонавир и метод за неговото получаване

Family Applications After (3)

Application Number Title Priority Date Filing Date
BG109682A BG65963B1 (bg) 1998-07-20 2006-09-20 Аморфен ритонавир и метод за неговото получаване
BG110080A BG110080A (bg) 1998-07-20 2006-09-20 Ритонавир, метод за неговото получаване и използването му
BG10110080A BG66140B1 (bg) 1998-07-20 2008-03-12 Фармацевтичен състав, съдържащ кристална форма іі ритонавир и метод за неговото получаване

Country Status (30)

Country Link
EP (4) EP1418174B1 (hu)
JP (4) JP4815050B2 (hu)
KR (3) KR100853371B1 (hu)
CN (5) CN1502613A (hu)
AR (5) AR019431A1 (hu)
AT (3) ATE261947T1 (hu)
AU (1) AU768207B2 (hu)
BG (4) BG65150B1 (hu)
BR (1) BR9912010A (hu)
CA (3) CA2510949C (hu)
CO (1) CO5090830A1 (hu)
CY (2) CY1111600T1 (hu)
CZ (2) CZ307116B6 (hu)
DE (2) DE69915628T2 (hu)
DK (3) DK2017269T3 (hu)
ES (3) ES2214038T3 (hu)
HK (2) HK1037918A1 (hu)
HU (3) HU227540B1 (hu)
ID (1) ID27996A (hu)
IL (4) IL140492A0 (hu)
MY (2) MY145265A (hu)
NO (2) NO318385B1 (hu)
NZ (2) NZ509125A (hu)
PL (2) PL213978B1 (hu)
PT (3) PT1418174E (hu)
SI (3) SI1418174T1 (hu)
SK (3) SK287586B6 (hu)
TR (1) TR200100171T2 (hu)
TW (3) TWI362382B (hu)
WO (1) WO2000004016A2 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir
EP1395249A1 (en) * 2001-05-25 2004-03-10 Abbott Laboratories Soft elastic capsules comprising ritonavir and/or lopinavir
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
EP1891027A1 (en) * 2005-05-30 2008-02-27 Ranbaxy Laboratories Limited Processes for the preparation of stable polymorphic form i of ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
EP2822553B1 (en) 2012-03-07 2016-05-18 ratiopharm GmbH Dosage form comprising non-crystalline lopinavir and crystalline ritonavir
US9370578B2 (en) 2012-03-07 2016-06-21 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484801A (en) * 1994-01-28 1996-01-16 Abbott Laboratories Pharmaceutical composition for inhibiting HIV protease
US5541206A (en) * 1989-05-23 1996-07-30 Abbott Laboratories Retroviral protease inhibiting compounds
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5725878A (en) * 1993-09-13 1998-03-10 Abbott Laboratories Pharmaceutical composition comprising HIV protease inhibiting compounds
WO1998022106A1 (en) * 1996-11-21 1998-05-28 Abbott Laboratories Pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DK1090914T3 (da) * 1992-12-29 2003-04-22 Abbott Lab Forbindelser, der inhiberer retroviral protease
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
MY145265A (en) * 1998-07-20 2012-01-13 Abbott Lab Amorphous ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
EP1183026B1 (en) * 1999-06-04 2006-07-05 Abbott Laboratories Improved pharmaceutical formulations comprising ritonavir

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541206A (en) * 1989-05-23 1996-07-30 Abbott Laboratories Retroviral protease inhibiting compounds
US5725878A (en) * 1993-09-13 1998-03-10 Abbott Laboratories Pharmaceutical composition comprising HIV protease inhibiting compounds
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5484801A (en) * 1994-01-28 1996-01-16 Abbott Laboratories Pharmaceutical composition for inhibiting HIV protease
WO1998022106A1 (en) * 1996-11-21 1998-05-28 Abbott Laboratories Pharmaceutical composition

Also Published As

Publication number Publication date
KR100793046B1 (ko) 2008-01-10
CA2674800A1 (en) 2000-01-27
PT2017269E (pt) 2011-12-20
BR9912010A (pt) 2001-04-10
CN1310715B (zh) 2010-11-03
JP4815050B2 (ja) 2011-11-16
PT1418174E (pt) 2009-06-08
EP2298751A2 (en) 2011-03-23
WO2000004016A3 (en) 2000-03-30
SK922001A3 (en) 2001-07-10
TWI271400B (en) 2007-01-21
AR049658A2 (es) 2006-08-23
SI1097148T1 (en) 2004-10-31
MY121765A (en) 2006-02-28
NO20042393L (no) 2001-01-18
CA2510949A1 (en) 2000-01-27
NZ509125A (en) 2003-02-28
NO20010298D0 (no) 2001-01-18
CZ2001203A3 (en) 2001-05-16
CO5090830A1 (es) 2001-10-30
DK1097148T3 (da) 2004-04-26
CZ298188B6 (cs) 2007-07-18
IL191582A0 (en) 2008-12-29
CA2337846A1 (en) 2000-01-27
CN102153524A (zh) 2011-08-17
CA2510949C (en) 2009-11-17
CN1502613A (zh) 2004-06-09
JP2002520410A (ja) 2002-07-09
PL213978B1 (pl) 2013-05-31
HU227540B1 (en) 2011-08-29
DK1418174T3 (da) 2009-05-18
TR200100171T2 (tr) 2001-05-21
ES2214038T3 (es) 2004-09-01
KR20060118022A (ko) 2006-11-17
BG105197A (en) 2001-10-31
ATE261947T1 (de) 2004-04-15
JP5732212B2 (ja) 2015-06-10
BG109682A (bg) 2007-03-30
ATE534636T1 (de) 2011-12-15
NZ522690A (en) 2004-04-30
CA2337846C (en) 2006-02-21
HU0800267D0 (en) 2008-06-30
ID27996A (id) 2001-05-03
TWI227713B (en) 2005-02-11
JP2014074047A (ja) 2014-04-24
EP1097148A2 (en) 2001-05-09
MY145265A (en) 2012-01-13
AR059764A2 (es) 2008-04-30
CY1112139T1 (el) 2015-11-04
CY1111600T1 (el) 2015-10-07
BG110080A (bg) 2008-11-28
BG66140B1 (bg) 2011-07-29
IL140492A (en) 2010-12-30
HU229999B1 (en) 2015-04-28
DE69915628T2 (de) 2004-08-12
PL194710B1 (pl) 2007-06-29
DE69915628D1 (en) 2004-04-22
EP2017269A3 (en) 2009-06-10
DK2017269T3 (da) 2012-03-05
CN101966180A (zh) 2011-02-09
BG65963B1 (bg) 2010-07-30
AU768207B2 (en) 2003-12-04
PT1097148E (pt) 2004-05-31
HK1037918A1 (en) 2002-02-22
HUP0103823A3 (en) 2003-05-28
SI1418174T1 (sl) 2009-08-31
KR100740796B1 (ko) 2007-07-20
HU0800266D0 (en) 2008-06-30
IL191582A (en) 2016-02-29
SK287586B6 (sk) 2011-03-04
EP1418174A3 (en) 2004-06-23
IL187181A (en) 2009-09-01
NO20010298L (no) 2001-01-18
EP2017269A9 (en) 2009-10-14
AR044029A2 (es) 2005-08-24
JP2017061475A (ja) 2017-03-30
CN101259128A (zh) 2008-09-10
SK287381B6 (sk) 2010-08-09
IL140492A0 (en) 2002-02-10
KR20040081137A (ko) 2004-09-20
DE69940616D1 (de) 2009-04-30
IL187181A0 (en) 2008-02-09
AU5003799A (en) 2000-02-07
AR019431A1 (es) 2002-02-20
EP2298751A3 (en) 2011-08-17
JP2010270135A (ja) 2010-12-02
NO318385B1 (no) 2005-03-14
EP2017269B1 (en) 2011-11-23
KR20010072003A (ko) 2001-07-31
AR059763A2 (es) 2008-04-30
EP2017269A8 (en) 2009-09-30
CZ2006533A3 (cs) 2001-05-16
NO327320B1 (no) 2009-06-08
SK286388B6 (sk) 2008-09-05
TW200716550A (en) 2007-05-01
HK1121155A1 (en) 2009-04-17
CN1310715A (zh) 2001-08-29
EP2017269A2 (en) 2009-01-21
CZ307116B6 (cs) 2018-01-24
HU230150B1 (hu) 2015-09-28
EP1418174A2 (en) 2004-05-12
ES2322759T3 (es) 2009-06-26
ES2372990T3 (es) 2012-01-30
HUP0103823A2 (hu) 2002-02-28
SI2017269T1 (sl) 2012-02-29
TWI362382B (en) 2012-04-21
EP1097148B1 (en) 2004-03-17
KR100853371B1 (ko) 2008-08-22
PL348033A1 (en) 2002-05-06
ATE425974T1 (de) 2009-04-15
WO2000004016A2 (en) 2000-01-27
EP1418174B1 (en) 2009-03-18

Similar Documents

Publication Publication Date Title
US9255092B2 (en) Polymorph of a pharmaceutical
BG110080A (bg) Ритонавир, метод за неговото получаване и използването му
AU2003254711B2 (en) Polymorph of a Pharmaceutical
AU2007202956B2 (en) Polymorph of a pharmaceutical